XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition

XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear. We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischae...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical biology 2020-01, Vol.58 (1), p.16-24
Hauptverfasser: Zhang, Yue-Ming, Qu, Xiao-Yu, Tao, Li-Na, Zhai, Jing-Hui, Gao, Huan, Song, Yan-Qing, Zhang, Si-Xi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 24
container_issue 1
container_start_page 16
container_title Pharmaceutical biology
container_volume 58
creator Zhang, Yue-Ming
Qu, Xiao-Yu
Tao, Li-Na
Zhai, Jing-Hui
Gao, Huan
Song, Yan-Qing
Zhang, Si-Xi
description XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear. We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury. Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed. Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro. XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.
doi_str_mv 10.1080/13880209.2019.1698619
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_13880209_2019_1698619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5c5a3ab22f194df0bc63a67036a7d385</doaj_id><sourcerecordid>2509430119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEoqXwE0CRuHDJ1t-xLwhU8bGoAgmKxM2ynfGuV0m8tZOiFX8eL7utKAdOtmaeecczfqvqOUYLjCQ6x1RKRJBaEITVAgslBVYPqlPcMtZwjMXDci9Ms4dOqic5bxBCnFL-uDqhWHJGCD-tfv0I4-qziZ_KUYdxA24KcazNAH2IyUyQawcJbDJ9HbJbGxiCOU-wheTnvEdL0Zx29U0w9bfl1yvcDNCFUtiVjO_NMJgplnyCvI1jhhJdBxv2XZ5Wj7zpMzw7nmfV9_fvri4-NpdfPiwv3l42jgsyNd5KpiRvQWLCLRPCW8bAA6XGtWCVY1aJTmJBgbaMqNYjSjtMWWt5x62lZ9XyoNtFs9HbFAaTdjqaoP8EYlppk6bgetDccUONJcRjxTqPrBPUiBZRYdqOSl60Xh-0trMtgzoYp7Kae6L3M2NY61W80UKJMgYuAq-OAilez5AnPZS9Qt-bEeKcNaFEtkxyRAr68h90E-c0llVpwpFiFGGsCsUPlEsx5wT-7jEY6b1V9K1V9N4q-miVUvfi70nuqm69UYA3B6D8Y0yD-RlT3-nJ7PqYfDKjC7nA_-3xG02e0Es</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509430119</pqid></control><display><type>article</type><title>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</title><source>Taylor &amp; Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhang, Yue-Ming ; Qu, Xiao-Yu ; Tao, Li-Na ; Zhai, Jing-Hui ; Gao, Huan ; Song, Yan-Qing ; Zhang, Si-Xi</creator><creatorcontrib>Zhang, Yue-Ming ; Qu, Xiao-Yu ; Tao, Li-Na ; Zhai, Jing-Hui ; Gao, Huan ; Song, Yan-Qing ; Zhang, Si-Xi</creatorcontrib><description>XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear. We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury. Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed. Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro. XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.</description><identifier>ISSN: 1388-0209</identifier><identifier>EISSN: 1744-5116</identifier><identifier>DOI: 10.1080/13880209.2019.1698619</identifier><identifier>PMID: 31854225</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Cerebral blood flow ; Cerebral infarction ; Chinese medicine ; Endothelial cells ; Inflammation ; Injection ; Ischemia ; Microvasculature ; Morphology ; pro-inflammatory response ; Reperfusion ; SIRT1 protein ; stroke</subject><ispartof>Pharmaceutical biology, 2020-01, Vol.58 (1), p.16-24</ispartof><rights>2019 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2019</rights><rights>2019 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2019 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</citedby><cites>FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</cites><orcidid>0000-0003-1685-6914</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968491/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968491/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31854225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yue-Ming</creatorcontrib><creatorcontrib>Qu, Xiao-Yu</creatorcontrib><creatorcontrib>Tao, Li-Na</creatorcontrib><creatorcontrib>Zhai, Jing-Hui</creatorcontrib><creatorcontrib>Gao, Huan</creatorcontrib><creatorcontrib>Song, Yan-Qing</creatorcontrib><creatorcontrib>Zhang, Si-Xi</creatorcontrib><title>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</title><title>Pharmaceutical biology</title><addtitle>Pharm Biol</addtitle><description>XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear. We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury. Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed. Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro. XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.</description><subject>Cerebral blood flow</subject><subject>Cerebral infarction</subject><subject>Chinese medicine</subject><subject>Endothelial cells</subject><subject>Inflammation</subject><subject>Injection</subject><subject>Ischemia</subject><subject>Microvasculature</subject><subject>Morphology</subject><subject>pro-inflammatory response</subject><subject>Reperfusion</subject><subject>SIRT1 protein</subject><subject>stroke</subject><issn>1388-0209</issn><issn>1744-5116</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhiMEoqXwE0CRuHDJ1t-xLwhU8bGoAgmKxM2ynfGuV0m8tZOiFX8eL7utKAdOtmaeecczfqvqOUYLjCQ6x1RKRJBaEITVAgslBVYPqlPcMtZwjMXDci9Ms4dOqic5bxBCnFL-uDqhWHJGCD-tfv0I4-qziZ_KUYdxA24KcazNAH2IyUyQawcJbDJ9HbJbGxiCOU-wheTnvEdL0Zx29U0w9bfl1yvcDNCFUtiVjO_NMJgplnyCvI1jhhJdBxv2XZ5Wj7zpMzw7nmfV9_fvri4-NpdfPiwv3l42jgsyNd5KpiRvQWLCLRPCW8bAA6XGtWCVY1aJTmJBgbaMqNYjSjtMWWt5x62lZ9XyoNtFs9HbFAaTdjqaoP8EYlppk6bgetDccUONJcRjxTqPrBPUiBZRYdqOSl60Xh-0trMtgzoYp7Kae6L3M2NY61W80UKJMgYuAq-OAilez5AnPZS9Qt-bEeKcNaFEtkxyRAr68h90E-c0llVpwpFiFGGsCsUPlEsx5wT-7jEY6b1V9K1V9N4q-miVUvfi70nuqm69UYA3B6D8Y0yD-RlT3-nJ7PqYfDKjC7nA_-3xG02e0Es</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Zhang, Yue-Ming</creator><creator>Qu, Xiao-Yu</creator><creator>Tao, Li-Na</creator><creator>Zhai, Jing-Hui</creator><creator>Gao, Huan</creator><creator>Song, Yan-Qing</creator><creator>Zhang, Si-Xi</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1685-6914</orcidid></search><sort><creationdate>20200101</creationdate><title>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</title><author>Zhang, Yue-Ming ; Qu, Xiao-Yu ; Tao, Li-Na ; Zhai, Jing-Hui ; Gao, Huan ; Song, Yan-Qing ; Zhang, Si-Xi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cerebral blood flow</topic><topic>Cerebral infarction</topic><topic>Chinese medicine</topic><topic>Endothelial cells</topic><topic>Inflammation</topic><topic>Injection</topic><topic>Ischemia</topic><topic>Microvasculature</topic><topic>Morphology</topic><topic>pro-inflammatory response</topic><topic>Reperfusion</topic><topic>SIRT1 protein</topic><topic>stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yue-Ming</creatorcontrib><creatorcontrib>Qu, Xiao-Yu</creatorcontrib><creatorcontrib>Tao, Li-Na</creatorcontrib><creatorcontrib>Zhai, Jing-Hui</creatorcontrib><creatorcontrib>Gao, Huan</creatorcontrib><creatorcontrib>Song, Yan-Qing</creatorcontrib><creatorcontrib>Zhang, Si-Xi</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yue-Ming</au><au>Qu, Xiao-Yu</au><au>Tao, Li-Na</au><au>Zhai, Jing-Hui</au><au>Gao, Huan</au><au>Song, Yan-Qing</au><au>Zhang, Si-Xi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</atitle><jtitle>Pharmaceutical biology</jtitle><addtitle>Pharm Biol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>58</volume><issue>1</issue><spage>16</spage><epage>24</epage><pages>16-24</pages><issn>1388-0209</issn><eissn>1744-5116</eissn><abstract>XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear. We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury. Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed. Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro. XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>31854225</pmid><doi>10.1080/13880209.2019.1698619</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1685-6914</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1388-0209
ispartof Pharmaceutical biology, 2020-01, Vol.58 (1), p.16-24
issn 1388-0209
1744-5116
language eng
recordid cdi_crossref_primary_10_1080_13880209_2019_1698619
source Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects Cerebral blood flow
Cerebral infarction
Chinese medicine
Endothelial cells
Inflammation
Injection
Ischemia
Microvasculature
Morphology
pro-inflammatory response
Reperfusion
SIRT1 protein
stroke
title XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=XingNaoJing%20injection%20ameliorates%20cerebral%20ischaemia/reperfusion%20injury%20via%20SIRT1-mediated%20inflammatory%20response%20inhibition&rft.jtitle=Pharmaceutical%20biology&rft.au=Zhang,%20Yue-Ming&rft.date=2020-01-01&rft.volume=58&rft.issue=1&rft.spage=16&rft.epage=24&rft.pages=16-24&rft.issn=1388-0209&rft.eissn=1744-5116&rft_id=info:doi/10.1080/13880209.2019.1698619&rft_dat=%3Cproquest_cross%3E2509430119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2509430119&rft_id=info:pmid/31854225&rft_doaj_id=oai_doaj_org_article_5c5a3ab22f194df0bc63a67036a7d385&rfr_iscdi=true